先瑞達醫療-B(06669.HK):首席執行官兼董事有意增持不超500萬港元股份
格隆匯9月16日丨先瑞達醫療-B(06669.HK)發佈公吿,董事會獲李靜女士(為首席執行官兼執行董事)吿知,其擬於該公吿日期起計約一星期內在公開市場上收購公司股份。增持股份代價的總金額預期不超過500萬港元。此外,據李女士表示,其擬持有將予收購的股份作中長期投資用途,且目前無意於增持股份後十二個月內出售有關股份。
董事會認為,建議增持股份充分顯示首席執行官對公司的前景及增長潛力充滿信心。於該公吿日期,李女士於54,949,087股股份中擁有權益,佔公司已發行股本總額約17.53%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.